Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Why AbbVie Stock Slumped Today
05:51pm, Thursday, 31'st Jul 2025
Shares of AbbVie (ABBV -0.24%) were bouncing along merrily for most of Thursday's trading session, until news of a fresh demand from the White House quashed the rally. Initially, the market was cheere
Trump pressures 17 pharma CEOs to cut US drug prices
02:28pm, Thursday, 31'st Jul 2025
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa
Trump posts letters to 17 pharmaceutical companies about drug prices
02:19pm, Thursday, 31'st Jul 2025
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
01:48pm, Thursday, 31'st Jul 2025
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
01:23pm, Thursday, 31'st Jul 2025
AbbVie Inc. NYSE: ABBV stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 earnings report. The biopharmaceutical giant reported global net revenue of
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
01:16pm, Thursday, 31'st Jul 2025
ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.
PCE Comes in Warmer Than Expected
12:11pm, Thursday, 31'st Jul 2025
PCE Comes in Warmer Than Expected.
Economy Heating Up on PCE for June
11:46am, Thursday, 31'st Jul 2025
Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
11:31am, Thursday, 31'st Jul 2025
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
09:55am, Thursday, 31'st Jul 2025
AbbVie (ABBV) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.89 per share. This compares to earnings of $2.65 per share a year ago.
AbbVie Stock Pops After Earnings Beat and Guidance Raised
08:08am, Thursday, 31'st Jul 2025
Second quarter EPS came in at $2.97 on revenue of $15.4 billion, beating analysts expectations.
AbbVie lifts annual profit forecast on strong demand for newer immunology drugs
07:51am, Thursday, 31'st Jul 2025
AbbVie raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq.
AbbVie Reports Second-Quarter 2025 Financial Results
07:44am, Thursday, 31'st Jul 2025
Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97, an Increase of 12.1 Percent; These Results Include an Unfavorable Impact of $0.4
AbbVie in talks to acquire Gilgamesh Pharmaceuticals
06:28pm, Wednesday, 30'th Jul 2025
Drugmaker AbbVie is in talks to acquire privately-held mental health therapeutics company Gilgamesh Pharmaceuticals in a deal worth about $1 billion, Bloomberg News reported on Wednesday, citing peopl
Sell AbbVie Stock Ahead of Its Upcoming Earnings?
09:30am, Wednesday, 30'th Jul 2025
AbbVie (NYSE:ABBV) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, understanding historical stock performance around earnings announcements can be a v
